uniQure NV (MEX:QUREN) Beneish M-Score: -2.85 (As of Jun. 27, 2026)

What is uniQure NV Beneish M-Score?

uniQure NV MEX:QUREN 29 Beneish M-Score is -2.85 as of Jun. 27, 2026. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, uniQure NV ranks better than 69.68% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for uniQure NV's Beneish M-Score or its related term are showing as below:

MEX:QUREN' s Beneish M-Score Range Over the Past 10 Years
Min: -12.85 Med: -2.54 Max: 80.36
Current: -2.85

During the past 13 years, the highest Beneish M-Score of uniQure NV was 80.36. The lowest was -12.85. And the median was -2.54.

uniQure NV Beneish M-Score Related Terms

uniQure NV Beneish M-Score Historical Data

* Premium members only.

The historical data trend for uniQure NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV Beneish M-Score Chart

uniQure NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

9.58

3.10

-3.19

-2.19

-3.14

uniQure NV Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															-3.68	-3.01	-3.71	-3.14	-2.85

MEX:QUREN vs NVAX, HRMY, IOVA: Beneish M-Score Comparison

For the Biotechnology subindustry, uniQure NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where uniQure NV's Beneish M-Score falls into.

Save Embed

29GF Score

uniQure NV MEX:QUREN

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

uniQure NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of uniQure NV for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.464

0.528 * 0.6124

0.404 * 0.7789

0.892 * 0.8503

0.115 * 0.8738

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1.714

4.679 * -0.085005

0.327 * 0.9405

-3.00

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was MXN64.2 Mil.
Revenue was 64.232 + 100.256 + 67.892 + 99.079 = MXN331.5 Mil.
Gross Profit was 60.283 + 92.423 + 60.591 + 86.727 = MXN300.0 Mil.
Total Current Assets was MXN11,103.5 Mil.
Total Assets was MXN14,042.2 Mil.
Property, Plant and Equipment(Net PPE) was MXN437.7 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN241.8 Mil.
Selling, General, & Admin. Expense(SGA) was MXN1,359.6 Mil.
Total Current Liabilities was MXN1,067.5 Mil.
Long-Term Debt & Capital Lease Obligation was MXN1,087.9 Mil.
Net Income was -965.381 + -667.759 + -1477.24 + -710.219 = MXN-3,820.6 Mil.
Non Operating Income was 0.433 + 319.637 + -141.177 + 332.486 = MXN511.4 Mil.
Cash Flow from Operations was -689.625 + -1396.684 + -300.827 + -751.191 = MXN-3,138.3 Mil.

Total Receivables was MXN51.6 Mil.
Revenue was 32.058 + 108.888 + 45.032 + 203.829 = MXN389.8 Mil.
Gross Profit was 28.028 + 95.978 + 24.928 + 67.143 = MXN216.1 Mil.
Total Current Assets was MXN8,907.9 Mil.
Total Assets was MXN12,385.5 Mil.
Property, Plant and Equipment(Net PPE) was MXN645.4 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN291.2 Mil.
Selling, General, & Admin. Expense(SGA) was MXN932.9 Mil.
Total Current Liabilities was MXN742.8 Mil.
Long-Term Debt & Capital Lease Obligation was MXN1,278.6 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(64.232 / 331.459)	/	(51.596 / 389.807)
	=	0.193786	/	0.132363
	=	1.464

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(216.077 / 389.807)	/	(300.024 / 331.459)
	=	0.554318	/	0.905162
	=	0.6124

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (11103.527 + 437.744) / 14042.172)	/	(1 - (8907.93 + 645.395) / 12385.456)
	=	0.178099	/	0.228666
	=	0.7789

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	331.459	/	389.807
	=	0.8503

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(291.171 / (291.171 + 645.395))	/	(241.758 / (241.758 + 437.744))
	=	0.310892	/	0.355787
	=	0.8738

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(1359.609 / 331.459)	/	(932.875 / 389.807)
	=	4.101892	/	2.393171
	=	1.714

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((1087.913 + 1067.482) / 14042.172)	/	((1278.597 + 742.837) / 12385.456)
	=	0.153494	/	0.16321
	=	0.9405

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-3820.599 - 511.379	-	-3138.327)	/	14042.172
	=	-0.085005

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

uniQure NV has a M-score of -3.00 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.85 mean?

uniQure NV (MEX:QUREN) has a Beneish M-Score of -2.85 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #252 out of 831 companies in the Biotechnology industry, placing it in the top 30.3%.

Is uniQure NV's Beneish M-Score too high?

uniQure NV's current Beneish M-Score is -2.85. Based on the distribution chart, uniQure NV ranks #252 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does uniQure NV's Beneish M-Score compare to NVAX and HRMY?

According to the Biotechnology industry distribution chart, uniQure NV ranks #252 out of 831 companies for Beneish M-Score. This puts uniQure NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on uniQure NV and its competitors. uniQure NV's current Beneish M-Score is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is uniQure NV stock overvalued right now?

Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current Beneish M-Score is -2.85. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current Beneish M-Score is -2.85 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (MEX:QUREN) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for MEX:QUREN:

Beneish M-Score: -2.85
GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Industry Healthcare Biotechnology

Comparable Companies NVAX HRMY IOVA NRIX ZYME AGIO ADMA CAPR SNDX SLS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges QURE:USA 0EE0:UK UQ1:Germany

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

29GF Score

Get the complete analysis for MEX:QUREN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN795.45

Price

MXN99.43

GF Value

View MEX:QUREN Analysis

See Beneish M-Score data for all stocks →